Small Molecules

29 Dec 2020 Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease
29 Dec 2020 FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
29 Dec 2020 Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
29 Dec 2020 Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
29 Dec 2020 Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
29 Dec 2020 Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
29 Dec 2020 European Medicines Agency Validates Bristol Myers Squibb’s Application for Zeposia (ozanimod) for the Treatment of Ulcerative Colitis
29 Dec 2020 LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
28 Dec 2020 First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial
24 Dec 2020 Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
23 Dec 2020 MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease
23 Dec 2020 Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs
23 Dec 2020 Cytokinetics Regains European Rights to Omecamtiv Mecarbil
23 Dec 2020 Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
23 Dec 2020 AMO Pharma Announces Initiation of Pivotal REACH-CDM Clinical Trial for AMO-02 in Treatment of Congenital Myotonic Dystrophy
23 Dec 2020 Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
22 Dec 2020 ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
22 Dec 2020 VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
22 Dec 2020 Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
22 Dec 2020 Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Us...
22 Dec 2020 BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
20 Dec 2020 Novartis receives complete response letter from U.S. FDA for inclisiran
20 Dec 2020 FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer
20 Dec 2020 U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
19 Dec 2020 Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up